When did LIGAND PHARMACEUTICALS (LGND) report earnings last quarter?
LIGAND PHARMACEUTICALS (LGND) last reported earnings on 2/26/2026.
LIGAND PHARMACEUTICALS (LGND) Earnings History & Surprises
NASDAQ:LGND • US53220K5048
Current stock price
202.91 USD
-8.57 (-4.05%)
At close:
202.91 USD
0 (0%)
After Hours:
LGND Earnings overview
Past quarterly earnings results for LIGAND PHARMACEUTICALS (LGND), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 6, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $1.79
- Revenue Estimate
- 59.657M
Last Reported
Most Recent- Release Date
- Feb 26, 2026
- Period
- Q4 / 2025
- EPS Reported
- $2.02
- EPS Surprise
- 26.84%
- Revenue Surprise
- 5.23%
Beat Rate
Last 8 Quarters 100%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 2.02 | 1.59 | 26.84% | 59.06% | 59.666M | 56.701M | 5.23% | 39.37% |
| Q3 2025 | 3.09 | 1.96 | 57.31% | 67.93% | 86.892M | 59.971M | 44.89% | 67.71% |
| Q2 2025 | 1.60 | 1.45 | 10.36% | 14.29% | 47.627M | 44.747M | 6.44% | 14.68% |
| Q1 2025 | 1.33 | 1.24 | 7.61% | 10.83% | 45.333M | 39.476M | 14.84% | 46.34% |
| Q4 2024 | 1.27 | 1.21 | 4.63% | -7.97% | 42.812M | 39.803M | 7.56% | 52.35% |
| Q3 2024 | 1.84 | 1.37 | 33.98% | 80.39% | 51.812M | 41.463M | 24.96% | 57.64% |
| Q2 2024 | 1.40 | 1.08 | 29.98% | -1.41% | 41.531M | 33.522M | 23.89% | 57.52% |
| Q1 2024 | 1.20 | 0.79 | 50.98% | -47.37% | 30.978M | 28.482M | 8.76% | -29.56% |
| Q4 2023 | 1.38 | 0.67 | 104.76% | 1.47% | 28.101M | 26.23M | 7.13% | 3.89% |
| Q3 2023 | 1.02 | 0.62 | 63.93% | -22.14% | 32.868M | 27.73M | 18.53% | -44.50% |
| Q2 2023 | 1.42 | 0.65 | 117.61% | 37.86% | 26.366M | 26.248M | 0.45% | -54.08% |
| Q1 2023 | 2.28 | 0.91 | 150.03% | 293.10% | 43.979M | 34.718M | 26.67% | 20.42% |
| Q4 2022 | 1.36 | 1.22 | 11.74% | -24.44% | 27.05M | 39.952M | -32.29% | -62.67% |
| Q3 2022 | 1.31 | 0.44 | 197.43% | -17.09% | 59.22M | 39.043M | 51.68% | -8.67% |
| Q2 2022 | 1.03 | 0.44 | 134.84% | -36.81% | 57.42M | 38.489M | 49.19% | -32.19% |
| Q1 2022 | 0.58 | 0.67 | -13.41% | -58.87% | 36.52M | 37.052M | -1.44% | -33.78% |
| Q4 2021 | 1.80 | 1.40 | 28.81% | 11.11% | 72.47M | 66.625M | 8.77% | 3.54% |
| Q3 2021 | 1.58 | 1.06 | 49.42% | 51.92% | 64.84M | 56.765M | 14.23% | 54.93% |
| Q2 2021 | 1.63 | 1.39 | 17.36% | 63.00% | 84.68M | 71.901M | 17.77% | 104.44% |
| Q1 2021 | 1.41 | 1.15 | 22.88% | 58.43% | 55.15M | 64.112M | -13.98% | 66.31% |
| Q4 2020 | 1.62 | 1.01 | 60.43% | - | 69.99M | 55.177M | 26.85% | - |
| Q3 2020 | 1.04 | 1.00 | 3.86% | - | 41.85M | 45.247M | -7.51% | - |
| Q2 2020 | 1.00 | 0.78 | 28.97% | - | 41.42M | 32.019M | 29.36% | - |
| Q1 2020 | 0.89 | 0.67 | 32.87% | - | 33.16M | 27.064M | 22.52% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
4
Average EPS beat (4)
19.98%
Max EPS beat (4)
57.31%
Min EPS beat (4)
4.63%
Revenue beat statistics
Revenue beat (4)
4
Average Revenue beat (4)
18.43%
Max Revenue beat (4)
44.89%
Min Revenue beat (4)
6.44%
Analysis
In the last 4 quarters, LGND has consistently beaten EPS estimates in all releases
LGND has consistently beaten revenue estimates in all past 4 earnings releases
In the last 4 quarters, LGND has beaten the EPS estimates by 20.0% on average.
In the last 4 quarters, LGND has beaten the revenue estimates by 18.4% on average.
Related analysis
LIGAND PHARMACEUTICALS / LGND Earnings FAQ
Did LIGAND PHARMACEUTICALS (LGND) beat earnings estimates last quarter?
LIGAND PHARMACEUTICALS (LGND) beat EPS estimates and beat revenue estimates in the most recent quarter.
How often does LIGAND PHARMACEUTICALS (LGND) beat earnings estimates?
In the last 4 quarters, LIGAND PHARMACEUTICALS (LGND) has beaten EPS estimates in 4 out of 4 releases.